These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27739357)

  • 41. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
    Zhao J; Cochrane CS; Najeeb J; Gooden D; Sciandra C; Fan P; Lemaitre N; Newns K; Nicholas RA; Guan Z; Thaden JT; Fowler VG; Spasojevic I; Sebbane F; Toone EJ; Duncan C; Gammans R; Zhou P
    Sci Transl Med; 2023 Aug; 15(708):eadf5668. PubMed ID: 37556556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crystal structure of A. aeolicus LpxC with bound product suggests alternate deacetylation mechanism.
    Miller MD; Gao N; Ross PL; Olivier NB
    Proteins; 2015 Sep; 83(9):1706-19. PubMed ID: 26177919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
    Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
    Barb AW; Zhou P
    Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
    Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
    Liang X; Lee CJ; Zhao J; Toone EJ; Zhou P
    J Med Chem; 2013 Sep; 56(17):6954-6966. PubMed ID: 23914798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure of the bacterial deacetylase LpxC bound to the nucleotide reaction product reveals mechanisms of oxyanion stabilization and proton transfer.
    Clayton GM; Klein DJ; Rickert KW; Patel SB; Kornienko M; Zugay-Murphy J; Reid JC; Tummala S; Sharma S; Singh SB; Miesel L; Lumb KJ; Soisson SM
    J Biol Chem; 2013 Nov; 288(47):34073-34080. PubMed ID: 24108127
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and biological evaluation of enantiomerically pure glyceric acid derivatives as LpxC inhibitors.
    Tangherlini G; Torregrossa T; Agoglitta O; Köhler J; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2016 Mar; 24(5):1032-44. PubMed ID: 26827141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Catalytic mechanism and molecular recognition of E. coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase probed by mutagenesis.
    Hernick M; Fierke CA
    Biochemistry; 2006 Dec; 45(51):15240-8. PubMed ID: 17176046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches.
    Sharma A; Kumar V; Pratap S; Kumar P
    Int J Biol Macromol; 2018 Oct; 118(Pt B):1747-1762. PubMed ID: 30017978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents.
    Kawai T; Kazuhiko I; Takaya N; Yamaguchi Y; Kishii R; Kohno Y; Kurasaki H
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1045-1049. PubMed ID: 28082037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding.
    Barb AW; Jiang L; Raetz CR; Zhou P
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18433-8. PubMed ID: 18025458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design.
    Lee CJ; Liang X; Chen X; Zeng D; Joo SH; Chung HS; Barb AW; Swanson SM; Nicholas RA; Li Y; Toone EJ; Raetz CR; Zhou P
    Chem Biol; 2011 Jan; 18(1):38-47. PubMed ID: 21167751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
    Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
    Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis, biological evaluation, and molecular docking studies of deoxygenated C-glycosides as LpxC inhibitors.
    Dreger A; Hoff K; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Chem; 2021 Dec; 117():105403. PubMed ID: 34758434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
    Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-Kinetic Relationship Studies for the Development of Long Residence Time LpxC Inhibitors.
    Basak S; Li Y; Tao S; Daryaee F; Merino J; Gu C; Delker SL; Phan JN; Edwards TE; Walker SG; Tonge PJ
    J Med Chem; 2022 Sep; 65(17):11854-11875. PubMed ID: 36037447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A fluorescence-based homogeneous assay for measuring activity of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase.
    Wang W; Maniar M; Jain R; Jacobs J; Trias J; Yuan Z
    Anal Biochem; 2001 Mar; 290(2):338-46. PubMed ID: 11237337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An explorative study on potent Gram-negative specific LpxC inhibitors: CoMFA, CoMSIA, HQSAR and molecular docking.
    Shiri F; Salahinejad M; Dijoor R; Nejati-Yazdinejad M
    J Recept Signal Transduct Res; 2018 Apr; 38(2):151-165. PubMed ID: 29623756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective mapping of chemical space for Pseudomonas aeruginosa deacetylase LpxC inhibitory potential.
    Kadam RU; Garg D; Roy N
    Chem Biol Drug Des; 2008 Jan; 71(1):45-56. PubMed ID: 18086152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.